These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Gaggin HK; Motiwala S; Bhardwaj A; Parks KA; Januzzi JL Circ Heart Fail; 2013 Nov; 6(6):1206-13. PubMed ID: 24114865 [TBL] [Abstract][Full Text] [Related]
5. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. Pascual-Figal DA; Ordoñez-Llanos J; Tornel PL; Vázquez R; Puig T; Valdés M; Cinca J; de Luna AB; Bayes-Genis A; J Am Coll Cardiol; 2009 Dec; 54(23):2174-9. PubMed ID: 19942089 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Shah RV; Chen-Tournoux AA; Picard MH; van Kimmenade RR; Januzzi JL Circ Heart Fail; 2009 Jul; 2(4):311-9. PubMed ID: 19808354 [TBL] [Abstract][Full Text] [Related]
7. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Hughes MF; Appelbaum S; Havulinna AS; Jagodzinski A; Zeller T; Kee F; Blankenberg S; Salomaa V; Heart; 2014 Nov; 100(21):1715-21. PubMed ID: 25080471 [TBL] [Abstract][Full Text] [Related]
8. The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure. Zhang R; Zhang Y; Zhang J; An T; Huang Y; Guo X; Januzzi JL; Cappola TP; Yin S; Wang Y; Zhou Q; Zou C; Ji S; Lv R PLoS One; 2014; 9(10):e110976. PubMed ID: 25347817 [TBL] [Abstract][Full Text] [Related]
10. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Januzzi JL; Pascual-Figal D; Daniels LB Am J Cardiol; 2015 Apr; 115(7 Suppl):70B-5B. PubMed ID: 25670638 [TBL] [Abstract][Full Text] [Related]
11. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Manzano-Fernández S; Januzzi JL; Pastor-Pérez FJ; Bonaque-González JC; Boronat-Garcia M; Pascual-Figal DA; Montalban-Larrea S; Navarro-Peñalver M; Andreu-Cayuelas JM; Valdés M Cardiology; 2012; 122(3):158-66. PubMed ID: 22832599 [TBL] [Abstract][Full Text] [Related]
12. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Mueller T; Dieplinger B; Gegenhuber A; Poelz W; Pacher R; Haltmayer M Clin Chem; 2008 Apr; 54(4):752-6. PubMed ID: 18375488 [TBL] [Abstract][Full Text] [Related]
13. Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency. Kim MS; Jeong TD; Han SB; Min WK; Kim JJ J Korean Med Sci; 2015 May; 30(5):569-75. PubMed ID: 25931787 [TBL] [Abstract][Full Text] [Related]
15. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Januzzi JL; Mebazaa A; Di Somma S Am J Cardiol; 2015 Apr; 115(7 Suppl):26B-31B. PubMed ID: 25665762 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Anand IS; Rector TS; Kuskowski M; Snider J; Cohn JN Circ Heart Fail; 2014 May; 7(3):418-26. PubMed ID: 24622243 [TBL] [Abstract][Full Text] [Related]
18. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Zhang K; Zhang XC; Mi YH; Liu J Chin Med J (Engl); 2013; 126(19):3628-31. PubMed ID: 24112154 [TBL] [Abstract][Full Text] [Related]